Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | Director | June 05, 2026 | June 10, 2026 |
| Artiva Biotherapeutics, Inc.ARTV · Entity 5404 | Chief Financial Officer | November 15, 2025 | November 18, 2025 |
| Latigo Biotherapeutics, Inc.LTGO · Entity 4709 | CFO and Chief Business Officer | August 06, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date June 05, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,901 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 5,778 · Balance 27,901 F1: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.23 · Expires 2036-06-05 | Direct | 16,667 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 16,667 · Balance 16,667 F2: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.
F2: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.
Artiva Biotherapeutics, Inc.
Report date November 15, 2025 · Filed November 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 99,356 |
Reported balance
After 2025-11-15 transaction · row 1
1 source rowRow 1 · 2025-11-15 · Tax withholding · Disposed 3,490 · Balance 99,356 F1: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.
Latigo Biotherapeutics, Inc.
Report date August 06, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.53 · Expires 2035-04-07 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-06 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares subject to this option shall vest in 48 equal monthly installments after April 8, 2025. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.53 · Expires 2035-04-07 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-06 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: One-fourth of the total shares subject to this option shall vest one year after April 8, 2025, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.98 · Expires 2036-02-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-06 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: One-fourth of the total shares subject to this option shall vest one year after February 2, 2026, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in 48 equal monthly installments after April 8, 2025. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
F2: One-fourth of the total shares subject to this option shall vest one year after April 8, 2025, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
F3: One-fourth of the total shares subject to this option shall vest one year after February 2, 2026, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kinnate Biopharma Inc.
Report date April 03, 2024 · Filed April 05, 2024
Section 16 reporting ended · disclosed 2024-04-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 1
1 source rowRow 1 · 2024-04-03 · Disposition to issuer · Disposed 64,087 · Balance 0 F1: Includes 42,188 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. F2: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for (i) $2.5879 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.26 · Expires 2031-06-07 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-04-03 · Disposition to issuer · Disposed 270,000 · Balance 0 F3: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.03 · Expires 2032-02-11 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-04-03 · Disposition to issuer · Disposed 185,000 · Balance 0 F3: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.78 · Expires 2033-02-10 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-04-03 · Disposition to issuer · Disposed 215,000 · Balance 0 F3: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 42,188 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer.
F2: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for (i) $2.5879 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR.
F3: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 10, 2026 01:20 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 16,667 | $0.00 Strike: $21.23 | $0.00 |
DisclosureSEC source: 0001628280-26-042039 · wk-form4_1781054445.xml · derivative · entry 2 Krishnamohan Neha · CIK 0001866171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires 2036-06-05 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Read SEC document |
| June 05, 2026 Filed Jun 10, 2026 01:20 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 5,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-042039 · wk-form4_1781054445.xml · nonDerivative · entry 1 Krishnamohan Neha · CIK 0001866171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,901 F1 · shares: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Read SEC document |
| November 15, 2025 Filed Nov 18, 2025 01:38 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Tax withholdingCommon Stock | 3,490 | $3.25 | $11,342.50 |
DisclosureSEC source: 0001193125-25-285005 · ownership.xml · nonDerivative · entry 1 Krishnamohan Neha · CIK 0001866171 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,356 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards. Read SEC document |
| November 13, 2025 Filed Nov 18, 2025 00:56 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 12,220 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001866171-25-000007 · wk-form4_1763427396.xml · derivative · entry 6 Krishnamohan Neha · CIK 0001866171 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,220 shares Expires 2033-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on August 14, 2025, by the Reporting Person, with a plan end date of November 2, 2026. F4 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023. Read SEC document |
| November 13, 2025 Filed Nov 18, 2025 00:56 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 27,052 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0001866171-25-000007 · wk-form4_1763427396.xml · derivative · entry 5 Krishnamohan Neha · CIK 0001866171 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,052 shares Expires 2034-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on August 14, 2025, by the Reporting Person, with a plan end date of November 2, 2026. F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. Read SEC document |
| November 13, 2025 Filed Nov 18, 2025 00:56 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,232 | $23.37 | $28,791.84 |
DisclosureSEC source: 0001866171-25-000007 · wk-form4_1763427396.xml · nonDerivative · entry 4 Krishnamohan Neha · CIK 0001866171 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,123 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on August 14, 2025, by the Reporting Person, with a plan end date of November 2, 2026. Read SEC document |
| November 13, 2025 Filed Nov 18, 2025 00:56 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 39,272 | $23.19 | $910,701.97 |
DisclosureSEC source: 0001866171-25-000007 · wk-form4_1763427396.xml · nonDerivative · entry 3 Krishnamohan Neha · CIK 0001866171 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,355 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on August 14, 2025, by the Reporting Person, with a plan end date of November 2, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $22.86 to $23.60, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 13, 2025 Filed Nov 18, 2025 00:56 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 12,220 | $7.51 | $91,772.20 |
DisclosureSEC source: 0001866171-25-000007 · wk-form4_1763427396.xml · nonDerivative · entry 2 Krishnamohan Neha · CIK 0001866171 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on August 14, 2025, by the Reporting Person, with a plan end date of November 2, 2026. Read SEC document |
| November 13, 2025 Filed Nov 18, 2025 00:56 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 27,052 | $8.63 | $233,458.76 |
DisclosureSEC source: 0001866171-25-000007 · wk-form4_1763427396.xml · nonDerivative · entry 1 Krishnamohan Neha · CIK 0001866171 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on August 14, 2025, by the Reporting Person, with a plan end date of November 2, 2026. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 00:15 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Tax withholdingCommon Stock | 5,813 | $2.75 | $15,985.75 |
DisclosureSEC source: 0001415889-25-022222 · form4-08182025_080805.xml · nonDerivative · entry 2 Krishnamohan Neha · CIK 0001866171 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,846 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards. Read SEC document |
| June 12, 2025 Filed Jun 17, 2025 00:17 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 20,568 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0002065881-25-000024 · wk-form4_1750119429.xml · derivative · entry 2 Krishnamohan Neha · CIK 0001866171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,568 Underlying: Common Stock · 20,568 shares Expires 2035-06-12 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Read SEC document |
| June 12, 2025 Filed Jun 17, 2025 00:17 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 7,609 | $0.00 | $0.00 |
DisclosureSEC source: 0002065881-25-000024 · wk-form4_1750119429.xml · nonDerivative · entry 1 Krishnamohan Neha · CIK 0001866171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,355 F1 · shares: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on November 15, 2024, maintained by the Company. Read SEC document |
| May 15, 2025 Filed Aug 19, 2025 00:15 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Tax withholdingCommon Stock | 1,341 | $2.13 | $2,856.33 |
DisclosureSEC source: 0001415889-25-022222 · form4-08182025_080805.xml · nonDerivative · entry 1 Krishnamohan Neha · CIK 0001866171 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,659 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 22:15 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006034 · form4-02282025_050204.xml · nonDerivative · entry 1 Krishnamohan Neha · CIK 0001866171 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 20:15 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-023361 · form4-09132024_040906.xml · nonDerivative · entry 1 Krishnamohan Neha · CIK 0001866171 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 27,052 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0001787306-24-000102 · wk-form4_1718743906.xml · derivative · entry 2 Krishnamohan Neha · CIK 0001866171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,052 Underlying: Common Stock · 27,052 shares Expires 2034-06-14 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 10,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-24-000102 · wk-form4_1718743906.xml · nonDerivative · entry 1 Krishnamohan Neha · CIK 0001866171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,746 F1 · shares: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:55 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Disposition to issuerStock Option (right to buy) · Derivative | 215,000 | Not disclosed Strike: $6.78 | Not disclosed |
DisclosureSEC source: 0001415889-24-010431 · form4-04052024_040421.xml · derivative · entry 4 Krishnamohan Neha · CIK 0001866171 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 215,000 shares Expires 2033-02-10 F3 · price: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. F3 · derivative.exercise_date: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:55 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Disposition to issuerStock Option (right to buy) · Derivative | 185,000 | Not disclosed Strike: $10.03 | Not disclosed |
DisclosureSEC source: 0001415889-24-010431 · form4-04052024_040421.xml · derivative · entry 3 Krishnamohan Neha · CIK 0001866171 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 185,000 shares Expires 2032-02-11 F3 · price: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. F3 · derivative.exercise_date: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:55 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Disposition to issuerStock Option (right to buy) · Derivative | 270,000 | Not disclosed Strike: $23.26 | Not disclosed |
DisclosureSEC source: 0001415889-24-010431 · form4-04052024_040421.xml · derivative · entry 2 Krishnamohan Neha · CIK 0001866171 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 270,000 shares Expires 2031-06-07 F3 · price: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. F3 · derivative.exercise_date: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:55 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Disposition to issuerCommon Stock | 64,087 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-010431 · form4-04052024_040421.xml · nonDerivative · entry 1 Krishnamohan Neha · CIK 0001866171 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 42,188 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. F2 · price: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for (i) $2.5879 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:00 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Tax withholdingCommon Stock | 1,506 | $2.59 | $3,900.54 |
DisclosureSEC source: 0001415889-24-006755 · form4-03052024_050310.xml · nonDerivative · entry 1 Krishnamohan Neha · CIK 0001866171 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,087 F1 · kind: The shares were forfeited to cover a tax obligation resulting form the quarterly vesting of restricted stock units ("RSUs") granted to the Reporting Person by the Issuer. F2 · balance_after: Includes 42,188 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 22:00 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Tax withholdingCommon Stock | 1,459 | $2.25 | $3,282.75 |
DisclosureSEC source: 0001209191-23-057455 · doc4.xml · nonDerivative · entry 1 Krishnamohan Neha · CIK 0001866171 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,593 F1 · kind: The shares were forfeited to cover a tax obligation resulting form the quarterly vesting of restricted stock units ("RSUs") granted to the Reporting Person by the Issuer. F2 · balance_after: Includes 46,407 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:00 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Tax withholdingCommon Stock | 1,459 | $2.35 | $3,428.65 |
DisclosureSEC source: 0001209191-23-048429 · doc4.xml · nonDerivative · entry 1 Krishnamohan Neha · CIK 0001866171 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,052 F1 · kind: The shares were forfeited to cover a tax obligation resulting form the quarterly vesting of RSU's granted to the Reporting Person by the Issuer. F2 · balance_after: Includes 50,625 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 21:00 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Tax withholdingCommon Stock | 1,459 | $4.30 | $6,273.70 |
DisclosureSEC source: 0001209191-23-034447 · doc4.xml · nonDerivative · entry 1 Krishnamohan Neha · CIK 0001866171 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,511 F1 · kind: The shares were forfeited to cover a tax obligation resulting form the quarterly vesting of RSU's granted to the Reporting Person by the Issuer. F2 · balance_after: Includes 54,844 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date. F3 · balance_after: Includes 2,592 shares acquired under the Issuers Employee Stock Purchase Plan in May 2023. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 22:59 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 12,220 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001787306-23-000052 · wk-form4_1685746757.xml · derivative · entry 2 Krishnamohan Neha · CIK 0001866171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,220 Underlying: Common Stock · 12,220 shares Expires 2033-05-31 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 22:59 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 4,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-23-000052 · wk-form4_1685746757.xml · nonDerivative · entry 1 Krishnamohan Neha · CIK 0001866171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,607 F1 · balance_after: Includes 4,375 Restricted Stock Units (?RSUs?). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:56 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Tax withholdingCommon Stock | 1,721 | $5.21 | $8,966.41 |
DisclosureSEC source: 0001209191-23-015868 · doc4.xml · nonDerivative · entry 1 Krishnamohan Neha · CIK 0001866171 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,378 F1 · kind: The shares were forfeited to cover a tax obligation resulting form the quarterly vesting of RSU's granted to the Reporting Person by the Issuer. F2 · balance_after: Includes 59,063 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:00 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | GrantEmployee Stock Option (right to buy) · Derivative | 215,000 | $0.00 Strike: $6.78 | $0.00 |
DisclosureSEC source: 0001209191-23-009207 · doc4.xml · derivative · entry 1 Krishnamohan Neha · CIK 0001866171 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 215,000 shares Expires 2033-02-10 F1 · derivative.exercise_date: One forty-eighth (1/48th) of the total number of shares granted under the Option shall vest and become exercisable starting on March 1, 2023 (the "Vesting Commencement Date") and thereafter each month on the same day of the month as the Vesting Commencement Date, until all shares subject to the Option have vested on February 1, 2027, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document |
| December 01, 2022 Filed Dec 3, 2022 01:00 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Tax withholdingCommon Stock | 1,459 | $7.75 | $11,307.25 |
DisclosureSEC source: 0001209191-22-059514 · doc4.xml · nonDerivative · entry 1 Krishnamohan Neha · CIK 0001866171 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,099 F1 · balance_after: Includes 1,543 shares acquired under the Issuer's Employee Stock Purchase Plan in November 2022. F2 · balance_after: Includes 63,282 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 23:08 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 29,482 | $0.00 Strike: $24.11 | $0.00 |
DisclosureSEC source: 0001567619-22-017088 · doc1.xml · derivative · entry 1 Krishnamohan Neha · CIK 0001866171 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,482 Underlying: Common Stock · 29,482 shares Expires 2032-09-02 F1 · derivative.exercise_date: The option vests as to 1/3rd of the total shares on each of September 2, 2023, September 2, 2024 and September 2, 2025, subject to Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 21:00 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | GrantCommon Stock | 67,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-048526 · doc4.xml · nonDerivative · entry 1 Krishnamohan Neha · CIK 0001866171 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,015 F1 · kind: The Issuer granted RSUs to the Reporting Person. Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date. F2 · balance_after: Includes 1,515 shares acquired under the Issuer's Employee Stock Purchase Plan in May 2022. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:01 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | GrantEmployee Stock Option (right to buy) · Derivative | 185,000 | $0.00 Strike: $10.03 | $0.00 |
DisclosureSEC source: 0001209191-22-009741 · doc4.xml · derivative · entry 1 Krishnamohan Neha · CIK 0001866171 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2032-02-11 F1 · derivative.exercise_date: One forty-eighth (1/48th) of the total number of shares granted under the Option shall vest and become exercisable starting on March 1, 2022 (the "Vesting Commencement Date") and thereafter each month on the same day of the month as the Vesting Commencement Date, until all shares subject to the Option have vested on February 1, 2026, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 00:32 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | GrantEmployee Stock Option (right to buy) · Derivative | 270,000 | $0.00 Strike: $23.26 | $0.00 |
DisclosureSEC source: 0001209191-21-039065 · doc4.xml · derivative · entry 1 Krishnamohan Neha · CIK 0001866171 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 270,000 shares Expires 2031-06-07 F1 · derivative.exercise_date: 1/4th of the shares underlying the Option shall vest and become exercisable one year from the date of grant (the "Vest Base Date"), and 1/36th of the remaining shares subject to the Option shall vest thereafter on the same day of the month as the Vest Base Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.